Literature DB >> 22231753

Equipoise: asking the right questions for clinical trial design.

Steven Joffe1, Franklin G Miller.   

Abstract

Randomized controlled trials (RCTs) are central to evidence-based clinical and health-policy decisions. However, RCTs highlight the tension between the therapeutic obligations of the physician and the scientific obligations of the investigator. Clinical equipoise, defined as honest professional disagreement among expert clinicians about the preferred treatment, is often cited as the solution to this RCT dilemma. Nevertheless, there are numerous practical and conceptual problems with the notion of equipoise. These problems include its mistaken imposition of therapeutic norms on the scientific enterprise of research, the difficulty of knowing when a state of equipoise exists, the susceptibility of expert judgment to bias and weak evidence, and its inability to support evidence necessary for health-policy decisions. An alternate approach to risk-benefit assessment that is congruent with the scientific purpose of RCTs can better guide ethical evaluation of these trials, as discussed in this Perspective.

Mesh:

Year:  2012        PMID: 22231753     DOI: 10.1038/nrclinonc.2011.211

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN: 1759-4774            Impact factor:   66.675


  30 in total

Review 1.  The ethical analysis of risk.

Authors:  C Weijer
Journal:  J Law Med Ethics       Date:  2000       Impact factor: 1.718

2.  Rehabilitating equipoise.

Authors:  Paul B Miller; Charles Weijer
Journal:  Kennedy Inst Ethics J       Date:  2003-06

3.  Linking insurance coverage for innovative invasive procedures with participation in clinical research.

Authors:  Franklin G Miller; Steven D Pearson
Journal:  JAMA       Date:  2011-11-09       Impact factor: 56.272

4.  At what level of collective equipoise does a clinical trial become ethical?

Authors:  N Johnson; R J Lilford; W Brazier
Journal:  J Med Ethics       Date:  1991-03       Impact factor: 2.903

5.  So-called "clinical equipoise" and the argument from design.

Authors:  Fred Gifford
Journal:  J Med Philos       Date:  2007 Mar-Apr

6.  Equipoise and the dilemma of randomized clinical trials.

Authors:  Franklin G Miller; Steven Joffe
Journal:  N Engl J Med       Date:  2011-02-03       Impact factor: 91.245

7.  Dispensing with equipoise.

Authors:  Franklin G Miller
Journal:  Am J Med Sci       Date:  2011-10       Impact factor: 2.378

8.  Oophorectomy and tamoxifen adjuvant therapy in premenopausal Vietnamese and Chinese women with operable breast cancer.

Authors:  Richard R Love; Nguyen Ba Duc; D Craig Allred; Nguyen Cong Binh; Nguyen Van Dinh; Nguyen Ngoc Kha; Tran Van Thuan; Syed K Mohsin; Le Dinh Roanh; Hoang Xuan Khang; Trinh Luong Tran; Tran Tu Quy; Nguyen Van Thuy; Pham Nhu Thé; Ton That Cau; Nguyen Dinh Tung; Dang Thanh Huong; Le Minh Quang; Nguyen Ngoc Hien; Le Thuong; Tian-Zhen Shen; Ye Xin; Qian Zhang; Thomas C Havighurst; Yonghong Fred Yang; Bruce E Hillner; David L DeMets
Journal:  J Clin Oncol       Date:  2002-05-15       Impact factor: 44.544

9.  Effect of awareness of a randomized controlled trial on use of experimental therapy.

Authors:  William F Clark; Amit X Garg; Peter G Blake; Gail A Rock; A Paul Heidenheim; David L Sackett
Journal:  JAMA       Date:  2003-09-10       Impact factor: 56.272

10.  Efficacy of oral ondansetron in the prevention of emesis in outpatients receiving cyclophosphamide-based chemotherapy. The Ondansetron Study Group.

Authors:  T M Beck; A A Ciociola; S E Jones; W H Harvey; N S Tchekmedyian; A Chang; D Galvin; N E Hart
Journal:  Ann Intern Med       Date:  1993-03-15       Impact factor: 25.391

View more
  11 in total

Review 1.  Role of randomized phase III trials in an era of effective targeted therapies.

Authors:  Manish R Sharma; Richard L Schilsky
Journal:  Nat Rev Clin Oncol       Date:  2011-12-06       Impact factor: 66.675

2.  Ethics of cancer clinical trials in low-resource settings.

Authors:  Steven Joffe; Franklin G Miller
Journal:  J Clin Oncol       Date:  2014-09-02       Impact factor: 44.544

Review 3.  What questions can a placebo answer?

Authors:  Spencer Phillips Hey; Charles Weijer
Journal:  Monash Bioeth Rev       Date:  2016-03

4.  Central Problem is Equipoise.

Authors:  Antonis G Tsamaloukas
Journal:  Dtsch Arztebl Int       Date:  2018-02-16       Impact factor: 5.594

5.  Neurobehavioral morbidity of pediatric mild sleep-disordered breathing and obstructive sleep apnea.

Authors:  Phoebe K Yu; Jerilynn Radcliffe; H Gerry Taylor; Raouf S Amin; Cristina M Baldassari; Thomas Boswick; Ronald D Chervin; Lisa M Elden; Susan L Furth; Susan L Garetz; Alisha George; Stacey L Ishman; Erin M Kirkham; Christopher Liu; Ron B Mitchell; S Kamal Naqvi; Carol L Rosen; Kristie R Ross; Jay R Shah; Ignacio E Tapia; Lisa R Young; David A Zopf; Rui Wang; Susan Redline
Journal:  Sleep       Date:  2022-02-12       Impact factor: 6.313

6.  Intellectual Equipoise and Challenges: Accruing Patients With Advanced Cancer to a Trial Randomizing to Surgical or Nonsurgical Management (SWOG S1316).

Authors:  Gary B Deutsch; Jeremiah L Deneve; Mazin F Al-Kasspooles; Valentine N Nfonsam; Camille C Gunderson; Angeles Alvarez Secord; Phillip Rodgers; Samantha Hendren; Eric J Silberfein; Marcia Grant; Jeff Sloan; Virginia Sun; Kathryn B Arnold; Garnet L Anderson; Robert S Krouse
Journal:  Am J Hosp Palliat Care       Date:  2019-05-23       Impact factor: 2.500

Review 7.  Prenatal effects of maternal consumption of polyphenol-rich foods in late pregnancy upon fetal ductus arteriosus.

Authors:  Paulo Zielinsky; Stefano Busato
Journal:  Birth Defects Res C Embryo Today       Date:  2013-12

8.  The combinatorial complexity of cancer precision medicine.

Authors:  Frederick Klauschen; Michael Andreeff; Ulrich Keilholz; Manfred Dietel; Albrecht Stenzinger
Journal:  Oncoscience       Date:  2014-07-23

Review 9.  Designing development programs for non-traditional antibacterial agents.

Authors:  John H Rex; Holly Fernandez Lynch; I Glenn Cohen; Jonathan J Darrow; Kevin Outterson
Journal:  Nat Commun       Date:  2019-07-31       Impact factor: 14.919

10.  The TOTAL trial dilemma: A survey among professionals on equipoise regarding fetal therapy for severe congenital diaphragmatic hernia.

Authors:  Simen Vergote; Daniel Pizzolato; Francesca Russo; Kris Dierickx; Jan Deprest; Neeltje Crombag
Journal:  Prenat Diagn       Date:  2020-11-05       Impact factor: 3.242

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.